Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?

Area of Science:

• Immunology and Oncology
• Cellular Therapy
• Regulatory Science

Background:

• T cells are potent immune effector cells.
• Bispecific antibodies and chimeric antigen receptor (CAR)-T cells are key T-cell engaging therapies.
• CAR-T cells are advanced therapy medicinal products (ATMPs) with complex development pathways.

Purpose of the Study:

• To review the current landscape of CAR-T cell therapies as a class of ATMPs.
• To examine the regulatory approval pathway for CAR-T therapies.
• To highlight challenges and future trends in CAR-T cell development.

Main Methods:

• Review of regulatory submissions and approval processes for CAR-T products.
• Analysis of challenges encountered in the development of cell- and gene-based therapies.
• Identification of emerging trends in the field of CAR-T therapy.

Main Results:

• The first bispecific antibodies and CAR-T cells have gained regulatory approval.
• CAR-T cell development presents significant challenges due to their complex nature.
• Recent approvals of CAR-T therapies (KYMRIAH, YESCARTA) are highly encouraging.

Conclusions:

• CAR-T cell therapy is a rapidly evolving field within ATMPs.
• Navigating regulatory pathways is crucial for successful CAR-T product development.
• Future trends indicate continued innovation and potential for broader clinical application.